ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 570,17
-0,82%
Dow Jones
40 211,72
0,53%
DAX
18 474,57
-0,68%
Brent Oil
83,62
-0,85%
Bitcoin
62 465,44
-3,68%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Portola Pharmaceuticals Inc (PTLA)

  7. Portola Pharmaceuticals Inc (PTLA) Actualités

PTLA

Portola Pharmaceuticals (PTLA)

Portola Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PTLA
DateHeureSourceTitreSymboleSociété
03/08/201814h00GlobeNewswire Inc.U.S. Centers for Medicare and Medicaid Services (CMS) Grants New Technology Add-On Payment for Portola Pharmaceuticals’ An...NASDAQ:PTLAPortola Pharmaceuticals Inc
02/08/201814h30GlobeNewswire Inc.Portola Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 201...NASDAQ:PTLAPortola Pharmaceuticals Inc
27/07/201814h24GlobeNewswire Inc.European CHMP Maintains Negative Opinion on Portola Pharmaceuticals’ Betrixaban Following AppealNASDAQ:PTLAPortola Pharmaceuticals Inc
06/07/201821h27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PTLAPortola Pharmaceuticals Inc
06/07/201821h23Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PTLAPortola Pharmaceuticals Inc
03/07/201814h30GlobeNewswire Inc.Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:PTLAPortola Pharmaceuticals Inc
25/06/201814h30GlobeNewswire Inc.Portola Pharmaceuticals Appoints 30-Year Industry Veteran Glenn Brame as Senior Vice President of Technical OperationsNASDAQ:PTLAPortola Pharmaceuticals Inc
11/06/201822h31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PTLAPortola Pharmaceuticals Inc
08/06/201823h23Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:PTLAPortola Pharmaceuticals Inc
06/06/201812h18Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:PTLAPortola Pharmaceuticals Inc
05/06/201822h30GlobeNewswire Inc.Portola Pharmaceuticals to Present at Two Upcoming Investor ConferencesNASDAQ:PTLAPortola Pharmaceuticals Inc
04/06/201822h30GlobeNewswire Inc.Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018NASDAQ:PTLAPortola Pharmaceuticals Inc
04/06/201814h30GlobeNewswire Inc.New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals’ Oral SYK/JAK Inhibitor C...NASDAQ:PTLAPortola Pharmaceuticals Inc
10/05/201822h58Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PTLAPortola Pharmaceuticals Inc
09/05/201822h05GlobeNewswire Inc.Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
04/05/201803h49GlobeNewswire Inc.U.S. FDA Approves Portola Pharmaceuticals’ Andexxa®, First and Only Antidote for the Reversal of Factor Xa InhibitorsNASDAQ:PTLAPortola Pharmaceuticals Inc
02/05/201815h33GlobeNewswire Inc.Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018NASDAQ:PTLAPortola Pharmaceuticals Inc
25/04/201819h06GlobeNewswire Inc.Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncolog...NASDAQ:PTLAPortola Pharmaceuticals Inc
24/04/201822h28Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PTLAPortola Pharmaceuticals Inc
13/04/201812h07Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:PTLAPortola Pharmaceuticals Inc
23/03/201814h06GlobeNewswire Inc.Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban i...NASDAQ:PTLAPortola Pharmaceuticals Inc
12/03/201817h12GlobeNewswire Inc.Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent Andex...NASDAQ:PTLAPortola Pharmaceuticals Inc
12/03/201813h30GlobeNewswire Inc.Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General CounselNASDAQ:PTLAPortola Pharmaceuticals Inc
05/03/201822h10GlobeNewswire Inc.Portola Pharmaceuticals to Host Webcast Event and Conference Call at ACC.18 to Discuss Late-Breaking Oral Presentation Highli...NASDAQ:PTLAPortola Pharmaceuticals Inc
28/02/201822h05GlobeNewswire Inc.Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
20/02/201822h47GlobeNewswire Inc.Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for Andexanet Alfa and BetrixabanNASDAQ:PTLAPortola Pharmaceuticals Inc
15/02/201822h05GlobeNewswire Inc.Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesda...NASDAQ:PTLAPortola Pharmaceuticals Inc
14/02/201823h15Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PTLAPortola Pharmaceuticals Inc
12/02/201816h01Edgar (US Regulatory)Schedule 13gNASDAQ:PTLAPortola Pharmaceuticals Inc
23/01/201803h33GlobeNewswire Inc.Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18NASDAQ:PTLAPortola Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PTLA

Dernières Valeurs Consultées

NASDAQ
STRT
Strattec Security
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés